Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) were down 8.8% during mid-day trading on Monday . The company traded as low as $22.27 and last traded at $22.23. Approximately 152,856 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 331,406 shares. The stock had previously closed at $24.38.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on HROW shares. B. Riley cut their price target on Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a research note on Wednesday, December 4th. HC Wainwright assumed coverage on shares of Harrow in a report on Thursday, February 6th. They set a "buy" rating and a $57.00 price objective for the company.
Read Our Latest Research Report on HROW
Harrow Stock Up 4.6 %
The stock's fifty day moving average price is $30.71 and its 200-day moving average price is $39.03. The company has a market capitalization of $828.80 million, a price-to-earnings ratio of -24.71 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.
Institutional Trading of Harrow
A number of hedge funds and other institutional investors have recently modified their holdings of HROW. Quest Partners LLC acquired a new position in shares of Harrow during the 3rd quarter worth approximately $29,000. GF Fund Management CO. LTD. bought a new stake in Harrow in the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC lifted its position in shares of Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after buying an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Harrow in the fourth quarter valued at approximately $78,000. Finally, AlphaQuest LLC boosted its stake in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.
Harrow Company Profile
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
